Acelrx pharmaceuticals inc (ACRX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue:
Revenue

2,289

2,151

7,995

-

-

-

-

-

-

-

-

Collaboration agreement

-

-

-

-

14,857

5,217

27,370

-

-

-

-

Contract and other

-

-

-

-

4,406

0

2,132

-

-

-

-

Research grant

-

-

-

-

-

-

-

2,394

1,072

-

-

Revenue

-

-

-

17,357

19,263

5,217

29,502

2,394

1,072

-

-

Operating costs and expenses:
Cost of goods sold

6,806

3,976

10,659

12,315

-

-

-

-

-

-

-

Cost of goods sold

-

-

-

-

1,770

0

-

-

-

-

-

Research and development

4,661

13,137

19,409

21,402

22,488

24,520

26,292

24,908

13,624

8,193

15,502

Selling, general and administrative

45,027

20,765

16,609

-

-

-

-

-

-

-

-

Total operating costs and expenses

56,494

37,878

46,677

-

-

-

-

-

-

-

-

General and administrative

-

-

-

15,597

14,203

18,346

9,877

7,199

6,800

3,993

3,529

Restructuring costs

-

-

-

-

756

0

-

-

-

-

-

Total operating costs and expenses

-

-

-

49,314

39,217

42,866

36,169

32,107

20,424

12,186

19,031

Loss from operations

-54,205

-35,727

-38,682

-31,957

-19,954

-37,649

-6,667

-

-

-

-

Other expense:
Interest income

-

-

-

-

-

-

-

-

-

-

33

Interest expense

2,535

2,217

3,316

2,770

2,977

2,639

1,518

2,283

2,309

1,397

1,242

Interest income and other (expense) income, net

2,166

1,138

510

918

1,720

6,935

-15,241

-

-

-

-

Non-cash interest income (expense) on liability related to future sale of royalties

-1,337

10,341

10,721

9,382

2,428

0

-

-

-

-

-

Total other expense

968

-11,420

-13,527

-11,234

-3,685

4,296

-16,759

-1,367

1,560

-761

121

Net loss before income taxes

-53,237

-47,147

-52,209

-43,191

-23,639

-

-

-29,713

-19,352

-12,186

-19,031

Net loss before income taxes

-

-

-

-

-

-33,353

-23,426

-

-

-

-

Provision (benefit) for income taxes

3

2

-701

-34

760

0

0

-

-

-

-

Net loss

-53,240

-47,149

-51,508

-43,157

-24,399

-33,353

-23,426

-33,363

-20,101

-14,344

-20,119

Other comprehensive loss:
Unrealized losses on available for sale securities

-

-

-3

4

3

-5

-

1

0

2

-

Comprehensive loss

-53,240

-47,149

-51,511

-43,153

-24,396

-33,358

-23,426

-33,362

-20,101

-14,342

-

Net loss per share of common stock, basic (in dollars per share)

-

-

-

-

-0.55

-0.77

-0.59

-1.51

-

-

-

Net loss per share of common stock, diluted (in dollars per share)

-

-

-

-

-0.60

-0.91

-0.59

-1.51

-

-

-

Shares used in computing net loss per share of common stock, basic (in shares)

-

-

-

-

44,300

43,427

39,746

22,124

-

-

-

Shares used in computing net loss per share of common stock, diluted see Note 14 (in shares)

-

-

-

-

44,468

44,322

39,746

22,124

-

-

-

Net loss per share of common stock, basic and diluted (in dollars per share)

-0.67

-0.81

-1.10

-0.95

-

-

-

-

-1.16

-21.84

-34.93

Shares used in computing net loss per share of common stock, basic and diluted – See Note 12 (in shares)

79,184

58,408

46,883

45,313

-

-

-

-

17,344

656

576

Product [Member]
Revenue

1,830

825

6,673

-

-

-

-

-

-

-

-

Contract and Other Collaboration [Member]
Revenue

459

1,326

1,322

-

-

-

-

-

-

-

-

Collaboration Agreement Revenue [Member]
Revenue

-

-

-

6,440

-

-

-

-

-

-

-

Contract and Other [Member]
Revenue

-

-

-

10,917

-

-

-

-

-

-

-